Skip to content

UNITED HEALTH PRODUCTS, INC.: 10-Q filed 2020-11-13

What UNITED HEALTH PRODUCTS, INC. reported in its quarterly report filed 2020-11-13 (fiscal Q3 2020): 29 published measures, 88 facts as tagged in accession 0001477932-20-006514.

This filing

Form
10-Q (quarterly report)
Filed
2020-11-13
Fiscal period
fiscal Q3 2020
Accession
0001477932-20-006514 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All UNITED HEALTH PRODUCTS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2020-09-30185,448USD
At 2019-12-3193,472USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2020-09-30-1,228,927USD
At 2020-06-30-816,786USD
At 2020-03-31-653,415USD
At 2019-12-31-903,805USD
At 2019-09-30-180,386USD
At 2019-06-30298,328USD
At 2019-03-31-338,092USD
At 2018-12-31-150,694USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2020-09-306,705USD
At 2019-12-3116,624USD
At 2019-09-3088,219USD
At 2018-12-3131,273USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2020-07-01 to 2020-09-30-9,221,359USD92
2020-01-01 to 2020-09-30-10,540,232USD274
2020-04-01 to 2020-06-30-693,052USD91
2020-01-01 to 2020-03-31-625,821USD91
2019-07-01 to 2019-09-30-524,869USD92
2019-01-01 to 2019-09-30-3,995,350USD273
2019-04-01 to 2019-06-30-807,083USD91
2019-01-01 to 2019-03-31-2,663,398USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2020-01-01 to 2020-09-30-1,180,494USD274
2019-01-01 to 2019-09-30-1,245,804USD273

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2020-01-01 to 2020-09-3092,089USD274
2019-01-01 to 2019-09-300USD273

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2020-07-01 to 2020-09-30136USD92
2020-01-01 to 2020-09-30563USD274
2019-07-01 to 2019-09-300USD92
2019-01-01 to 2019-09-304,927USD273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2020-01-01 to 2020-09-301,262,664USD274
2019-01-01 to 2019-09-301,302,750USD273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2020-01-01 to 2020-09-30-92,089USD274
2019-01-01 to 2019-09-300USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2020-09-30-36,668,091USD
At 2019-12-31-26,127,859USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2020-09-3092,089USD
At 2019-12-310USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2020-01-01 to 2020-09-308,786,547USD274
2019-01-01 to 2019-09-302,401,000USD273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2020-07-01 to 2020-09-30-9,105,799USD92
2020-01-01 to 2020-09-30-10,377,481USD274
2019-07-01 to 2019-09-30-478,715USD92
2019-01-01 to 2019-09-30-3,746,444USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2020-09-3093,359USD
At 2019-12-3193,472USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2020-07-01 to 2020-09-3052,726USD92
2020-01-01 to 2020-09-3060,495USD274
2019-07-01 to 2019-09-3046,154USD92
2019-01-01 to 2019-09-30248,906USD273

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2020-09-301,414,375USD
At 2019-12-31997,277USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2020-07-01 to 2020-09-309,105,901USD92
2020-01-01 to 2020-09-3010,377,849USD274
2019-07-01 to 2019-09-30478,715USD92
2019-01-01 to 2019-09-303,750,869USD273

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2020-09-3076,654USD
At 2019-12-3176,848USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2020-07-01 to 2020-09-30102USD92
2020-01-01 to 2020-09-30368USD274
2019-07-01 to 2019-09-300USD92
2019-01-01 to 2019-09-304,425USD273

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2020-07-01 to 2020-09-309,045,859USD92
2020-01-01 to 2020-09-3010,287,132USD274
2019-07-01 to 2019-09-30328,721USD92
2019-01-01 to 2019-09-303,358,606USD273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2020-07-01 to 2020-09-3060,042USD92
2020-01-01 to 2020-09-3090,717USD274
2019-07-01 to 2019-09-30149,994USD92
2019-01-01 to 2019-09-30392,263USD273

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2020-09-3035,250,891USD
At 2019-12-3125,045,754USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2020-09-30174,121USD
At 2019-12-31119,016USD

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2020-07-01 to 2020-09-30-115,560USD92
2020-01-01 to 2020-09-30-162,751USD274
2019-07-01 to 2019-09-30-46,154USD92
2019-01-01 to 2019-09-30-248,906USD273

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2020-01-01 to 2020-09-300USD274
2019-01-01 to 2019-09-300USD273

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

PeriodValueUnitDays
2020-01-01 to 2020-09-300USD274
2019-01-01 to 2019-09-300USD273

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2020-01-01 to 2020-09-301,105,696USD274
2019-01-01 to 2019-09-301,110,750USD273

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2020-01-01 to 2020-09-300USD274
2019-01-01 to 2019-09-30-4,927USD273

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2020-01-01 to 2020-09-30194USD274
2019-01-01 to 2019-09-30-35,319USD273

Inspect the source

Entity
UNITED HEALTH PRODUCTS, INC. / CIK 0001096938
Captured
2026-09-20T05:22:35.874Z
SEC response SHA-256
ac6cf9d703c0adca8f17a2c8b6ab295df7496239afbd8b7d9c595d23b1e2267e

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001096938.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))